Catalogo Articoli (Spogli Riviste)

HELP
ATTENZIONE: attualmente gli articoli Current Contents (fonte ISI) a partire dall'anno 2002 sono consultabili sulla Risorsa On-Line

Le informazioni sugli articoli di fonte ISI sono coperte da copyright

La ricerca find articoli where authors phrase all words ' GISSELBRECHT C' sort by level,fasc_key/DESCEND, pagina_ini_num/ASCEND ha restituito 132 riferimenti
Si mostrano 100 riferimenti a partire da 1
Selezionare un intervallo

Per ulteriori informazioni selezionare i riferimenti di interesse.

    1. Bosly, A; Haioun, C; Gisselbrecht, C; Reyes, F; Coiffier, B
      High-dose treatment with autologous stem cell transplantation versus sequential chemotherapy: the GELA experience

      EUROPEAN JOURNAL OF HAEMATOLOGY
    2. Bosly, A; Gisselbrecht, C
      Intensification with autologous transplantation in non-Hodgkin's lymphomas

      BULLETIN DU CANCER
    3. Ionescu, I; Brice, P; Simon, D; Guermazi, A; Leblanc, T; Rousselot, P; Gossot, D; Meignin, V; Gisselbrecht, C; Rain, JD
      Restaging with gallium scan identifies chemosensitive patients and predicts survival of poor-prognosis mediastinal Hodgkin's disease patients

      MEDICAL ONCOLOGY
    4. Foran, JM; Cunningham, D; Coiffier, B; Solal-Celigny, P; Reyes, F; Ghielmini, M; Johnson, PWM; Gisselbrecht, C; Bradburn, M; Matthews, J; Lister, TA
      Treatment of mantle-cell lymphoma with Rituximab (chimeric monoclonal anti-CD20 antibody): Analysis of factors associated with response

      ANNALS OF ONCOLOGY
    5. Foran, JM; Rohatiner, AZS; Cunningham, D; Popescu, RA; Solal-Celigny, P; Ghielmini, M; Coiffier, B; Johnson, PWM; Gisselbrecht, C; Reyes, F; Radford, JA; Bessell, EM; Souleau, B; Benzohra, A; Lister, TA
      European phase II study of rituximab (chimeric anti-CD20 monoclonal antibody) for patients with newly diagnosed mantle-cell lymphoma and previously treated mantle-cell lymphoma, immunocytoma, and small B-cell lymphocytic lymphoma

      JOURNAL OF CLINICAL ONCOLOGY
    6. Mounier, N; Gisselbrecht, C
      Myelodysplasia after autotransplantation

      JOURNAL OF CLINICAL ONCOLOGY
    7. Haioun, C; Lepage, E; Gisselbrecht, C; Salles, G; Coiffier, B; Brice, P; Bosly, A; Morel, P; Nouvel, C; Tilly, H; Lederlin, P; Sebban, C; Briere, J; Gaulard, P; Reyes, F
      Survival benefit of high-dose therapy in poor-risk aggressive non-Hodgkin's lymphoma: Final analysis of the prospective LNH87-2 protocol - A Groupe d'Etude des Lymphomes de l'Adulte Study

      JOURNAL OF CLINICAL ONCOLOGY
    8. Casasnovas, RO; Haioun, C; Dumontet, C; Gabarre, J; Richard, B; Lederlin, P; Caillot, D; Stamatoullas, A; Morel, P; Quesnel, B; Blay, JY; Bouabdallah, K; Gisselbrecht, C
      Phase II study of 3-hour infusion of high dose paclitaxel in refractory and relapsed aggressive non-Hodgkin's lymphomas

      HAEMATOLOGICA
    9. Park, S; Brice, P; Noguerra, ME; Simon, D; Rousselot, P; Kerneis, Y; Morel, P; Marolleau, JP; Gisselbrecht, C
      Myelodysplasias and leukemias after autologous stem cell transplantation for lymphoid malignancies

      BONE MARROW TRANSPLANTATION
    10. Decaudin, D; Brousse, N; Brice, P; Haioun, C; Bourhis, JH; Morel, P; Van Hoof, A; Souleau, B; Quesnel, B; Gisselbrecht, C
      Efficacy of autologous stem cell transplantation in mantle cell lymphoma: a 3-year follow-up study

      BONE MARROW TRANSPLANTATION
    11. Meignin, V; Briere, J; Brice, P; Gisselbrecht, C; Gaulard, P; Janin, A
      Lymphocytic predominant Hodgkin's disease or type I Hodgkin's disease (paragranuloma of Poppema-Lennert): a clinicopathological entity. Study of 21 cases and review of the literature

      ANNALES DE PATHOLOGIE
    12. Adida, C; Haioun, C; Gaulard, P; Lepage, E; Morel, P; Briere, J; Dombret, H; Reyes, F; Diebold, J; Gisselbrecht, C; Salles, G; Altieri, DC; Molina, TJ
      Prognostic significance of survivin expression in diffuse large B-cell lymphomas

      BLOOD
    13. Mounier, N; Haioun, C; Cole, BF; Gisselbrecht, C; Sebban, C; Morel, P; Marit, G; Bouabdallah, R; Ravoet, C; Salles, G; Reyes, F; Lepage, E
      Quality of life-adjusted survival analysis of high-dose therapy with autologous bone marrow transplantation versus sequential chemotherapy for patients with aggressive lymphoma in first complete remission

      BLOOD
    14. Lotz, JP; Cure, H; Janvier, M; Morvan, F; Legros, M; Asselain, B; Guillemot, M; Roche, H; Gisselbrecht, C
      High-dose chemotherapy with autologous hematopoietic stem cell support formetastatic breast cancer: Results of the French Pegase 04 protocol

      HEMATOLOGY AND CELL THERAPY
    15. Errante, D; Gabarre, J; Ridolfo, AL; Rossi, G; Nosari, AM; Gisselbrecht, C; Kerneis, Y; Mazzetti, E; Vaccher, E; Talamini, R; Carbone, A; Tirelli, U
      Hodgkin's disease in 35 patients with HIV infection: An experience with epirubicin, bleomycin, vinblastine and prednisone chemotherapy in combinationwith antiretroviral therapy and primary use of G-CSF

      ANNALS OF ONCOLOGY
    16. Farge, D; Breban, M; Guillevin, L; Piette, JC; Cabane, J; Cherin, P; Cosserat, J; Sicard, D; Ribaud, P; Marolleau, JP; Bouscary, D; Mariette, X; Gisselbrecht, C; Gluckman, E
      Bone marrow graft for the treatment of autoimmune diseases

      PRESSE MEDICALE
    17. Andre, M; Henry-Amar, M; Pico, JL; Brice, P; Blaise, D; Kuentz, M; Coiffier, B; Colombat, P; Cahn, JY; Attal, M; Fleury, J; Milpied, N; Nedellec, G; Biron, P; Tilly, H; Jouet, JP; Gisselbrecht, C
      Comparison of high-dose therapy and autologous stem-cell transplantation with conventional therapy for Hodgkin's disease induction failure: A case-control study

      JOURNAL OF CLINICAL ONCOLOGY
    18. Fitoussi, O; Simon, D; Brice, P; Makke, J; Scrobohaci, ML; Triki, TB; Hennequin, C; Ferme, C; Gisselbrecht, C
      Tandem transplant of peripheral blood stem cells for patients with poor-prognosis Hodgkins's disease or non-Hodgkin's lymphoma

      BONE MARROW TRANSPLANTATION
    19. Marolleau, JP; Dal Cortivo, L; Mills, B; Fermand, JP; Miclea, JM; Lotz, JP; Gisselbrecht, C; Benbunan, M
      Enrichment of peripheral blood CD34(+) cells for transplantation using a fully automated immunomagnetic cell selection system and a novel octapeptidereleasing agent

      BONE MARROW TRANSPLANTATION
    20. CAMPO E; GAULARD P; ZUCCA E; JAFFE ES; HARRIS NL; DIEBOLD J; SCHLEGELBERGER B; FELLER AC; DELSOL C; GISSELBRECHT C; MONTSERRAT E
      REPORT OF THE EUROPEAN TASK-FORCE ON LYMPHOMAS - WORKSHOP ON PERIPHERAL T-CELL LYMPHOMAS

      Annals of oncology
    21. HAIOUN C; LEPAGE E; GISSELBRECHT C; COIFFIER B; DOYEN C; MOREL P; ATTAL M; TILLY H; DECONINCK E; GAULARD P; REYES F
      HIGH-DOSE THERAPY FOLLOWED BY STEM-CELL TRANSPLANTATION IN PARTIAL-RESPONSE AFTER FIRST-LINE INDUCTION THERAPY FOR AGGRESSIVE NON-HODGKINS-LYMPHOMA

      Annals of oncology
    22. MOUNIER N; GISSELBRECHT C
      CONDITIONING REGIMENS BEFORE TRANSPLANTATION IN PATIENTS WITH AGGRESSIVE NON-HODGKINS-LYMPHOMA

      Annals of oncology
    23. BRICE P; CAZALS D; MOUNIER N; VEROLA O; NEIDHARTBERARD AM; REMENIERAS L; DECONINCK E; DOYEN C; HAMELSAND J; MOLINA T; MOULONGUET I; GISSELBRECHT C
      PRIMARY CUTANEOUS LARGE-CELL LYMPHOMA - ANALYSIS OF 49 PATIENTS INCLUDED IN THE LNH87 PROSPECTIVE TRIAL OF POLYCHEMOTHERAPY FOR HIGH-GRADE LYMPHOMAS

      Leukemia
    24. COLE BF; SOLALCELIGNY P; GELBER RD; LEPAGE E; GISSELBRECHT C; REYES F; SEBBAN C; SUGANO D; TENDLER C; GOLDHIRSCH A
      QUALITY-OF-LIFE-ADJUSTED SURVIVAL ANALYSIS OF INTERFERON-ALPHA-2B TREATMENT FOR ADVANCED FOLLICULAR LYMPHOMA - AN AID TO CLINICAL DECISION-MAKING

      Journal of clinical oncology
    25. LUNDIN J; OSTERBORG A; BRITTINGER G; CROWTHER D; DOMBRET H; ENGERT A; EPENETOS A; GISSELBRECHT C; HUHN D; JAEGER U; THOMAS J; MARCUS R; NISSEN N; POYNTON C; RANKIN E; STAHEL R; UPPENKAMP M; WILLEMZE R; MELLSTEDT H
      CAMPATH-1H MONOCLONAL-ANTIBODY IN THERAPY FOR PREVIOUSLY TREATED LOW-GRADE NON-HODGKINS-LYMPHOMAS - A PHASE-II MULTICENTER STUDY

      Journal of clinical oncology
    26. GUGLIELMI C; GOMEZ F; PHILIP T; HAGENBEEK A; MARTELLI M; SEBBAN C; MILPIED N; BRON D; CAHN JY; SOMERS R; SONNEVELD P; GISSELBRECHT C; VANDERLELIE H; CHAUVIN F
      TIME TO RELAPSE HAS PROGNOSTIC VALUE IN PATIENTS WITH AGGRESSIVE LYMPHOMA ENROLLED ONTO THE PARMA TRIAL

      Journal of clinical oncology
    27. MOREAU P; FLEURY J; BRICE P; COLOMBAT P; BOUABDALLAH R; LIOURE B; VOILLAT L; CASASNOVAS O; FRANCOIS S; SADOUN A; LAMY T; LOTZ JP; MUNCK JN; DIVINE M; FERME C; PENY AM; FRUCHART C; ORIOL P; OJEDA M; REMAN O; MILPIED N; GISSELBRECHT C; LEGROS M; HAROUSSEAU JL
      EARLY INTENSIVE THERAPY WITH AUTOLOGOUS STEM-CELL TRANSPLANTATION IN ADVANCED HODGKINS-DISEASE - RETROSPECTIVE ANALYSIS OF 158 CASES FROM THE FRENCH REGISTRY

      Bone marrow transplantation
    28. BOSLY A; SONET A; SALLES G; BRICE P; HAIOUN C; KERNEIS Y; FERRANT A; TILLY H; LEDERLIN P; PLANTIER I; SEBBAN C; GISSELBRECHT C; COIFFIER B
      SUPERIORITY OF LATE OVER EARLY INTENSIFICATION IN RELAPSING REFRACTORY AGGRESSIVE NON-HODGKINS-LYMPHOMA - A RANDOMIZED STUDY FROM THE GELA - LNH RP-93/

      Bone marrow transplantation
    29. SIMON D; HAIOUN C; GAULARD P; SALLES G; TILLY H; BOSLY A; DIEBOLD J; GISSELBRECHT C
      AUTOLOGOUS STEM-CELL TRANSPLANTATION IN PTCL

      Bone marrow transplantation
    30. PHILIP T; GOMEZ F; GUGLIELMI C; HAGENBEEK A; SEBBAN C; MILPIED N; BRON D; CAHN JY; SOMERS R; SONNEVELD P; GISSELBRECHT C; VANDERLELIE H; CHAUVIN F
      LONG-TERM OUTCOME OF RELAPSED NON-HODGKINS-LYMPHOMA (NHL) PATIENTS INCLUDED IN THE PARMA TRIAL - INCIDENCE OF LATE RELAPSES, LONG-TERM TOXICITY AND IMPACT OF THE INTERNATIONAL PROGNOSTIC INDEX (IPI) AT RELAPSE

      Bone marrow transplantation
    31. MILPIED N; ATTAL M; GISSELBRECHT C; MARIT G; TANGUY ML; PICO JL; IFRAH N
      LYMPHOBLASTIC LYMPHOMA (LBL) - WHAT IS THE BEST TIME FOR TRANSPLANTATION (BMT) - A STUDY FROM SFGM

      Bone marrow transplantation
    32. HAIOUN C; LEPAGE E; GISSELBRECHT C; COIFFIER B; DOYEN C; MOREL P; ARTAL M; TILLY H; DECONINCK E; GAULARD P; REYES F
      AUTOLOGOUS TRANSPLANTATION VERSUS CONVENTIONAL SALVAGE THERAPY IN AGGRESSIVE NON-HODGKINS-LYMPHOMA (NHL) PARTIALLY RESPONDING TO FIRST LINECHEMOTHERAPY - A STUDY OF 94 PATIENTS ENROLLED IN THE LNH87-2 PROTOCOL

      Bone marrow transplantation
    33. HAIOUN C; GISSELBRECHT C; QUESNEL B; MOREL P; REYES F
      DOUBLE AUTOTRANSPLANT (DAT) AS FIRST LINE CONSOLIDATIVE TREATMENT IN POOR-RISK AGGRESSIVE LYMPHOMA - A PILOT-STUDY OF 31 PATIENTS

      Bone marrow transplantation
    34. GUGLIELMI C; GOMEZ F; HAGENBEEK A; SEBBAN C; MARTELLI M; MILPIED N; BRON D; CAHN JY; SOMERS R; SONNEVELD P; GISSELBRECHT C; VANDERLELIE H; CHAUVIN F; PHILIP T
      TIME TO RELAPSE HAS PROGNOSTIC VALUE IN AGGRESSIVE LYMPHOMA ENROLLED IN THE PARMA TRIAL AT FIRST RELAPSE

      Bone marrow transplantation
    35. MOUNIER N; GISSELBRECHT C; LEPAGE E
      TREATMENT OF INTERMEDIATE-GRADE AND HIGH-GRADE NON-HODGKINS-LYMPHOMA

      The New England journal of medicine
    36. MOUNIER N; MOREL P; HAIOUN C; COIFFIER B; TILLY H; CHATELAIN C; LEDERLIN P; THYSS A; HERBRECHT R; GISSELBRECHT C; LEPAGE E
      A MULTIVARIATE-ANALYSIS OF THE SURVIVAL OF PATIENTS WITH AGGRESSIVE LYMPHOMA - VARIATIONS IN THE PREDICTIVE VALUE OF PROGNOSTIC FACTORS DURING THE COURSE OF THE DISEASE

      Cancer
    37. SIMON D; GISSELBRECHT C; SEBBAN C; REYES F; BOSLY A; GABARRE J; MOREL P; BOULAT O; LEPAGE E
      SYSTEM OF THERAPEUTIC DECISION-MAKING FOR G-CSF PRESCRIPTION IN AGGRESSIVE NON-HODGKIN LYMPHOMAS

      British Journal of Haematology
    38. BOSLY A; SONET A; SALLES G; BRICE P; HAIOUN C; KERNEIS Y; FERRANT A; TILLY H; LEDERLIN P; PLANTIER I; SEBBAN C; GISSELBRECHT C; COIFFIER B
      SUPERIORITY OF LATE OVER EARLY INTENSIFICATION IN RELAPSING REFRACTORY AGGRESSIVE NON-HODGKINS-LYMPHOMA - A RANDOMIZED STUDY FROM THE GELA - LNH-RP-93/

      British Journal of Haematology
    39. FORAN JM; ROHATINER AZS; CUNNINGHAM D; POPESCU R; SOLAICELIGNY P; CAVALLI F; COIFFIER B; JOHNSON P; GISSELBRECHT C; HAIOUN C; BESSELL E; SWEETENHAM J; RADFORD J; BENZOHRA A; LISTER TA
      IMMUNOTHERAPY OF MANTLE CELL LYMPHOMA (MCL), LYMPHOPLASMACYTOID LYMPHOMA (LPC) AND WALDENSTROMS MACROGLOBULINEMIA (WM), AND SMALL LYMPHOCYTIC LYMPHOMA (SLL) WITH RITUXIMAB (IDEC-C288) - PRELIMINARY-RESULTS OF AN ONGOING INTERNATIONAL MULTICENTER TRIAL

      British Journal of Haematology
    40. LANGOUET AM; SIMON D; BRICE P; REYES F; SALLES G; TILLY H; FARINOTTI R; FAURE P; LEPAGE E; GISSELBRECHT C
      FACTORS INFLUENCING HEMATOLOGIC RECOVERY AFTER PERIPHERAL-BLOOD STEM-CELL TRANSPLANTATION IN AGGRESSIVE NON-HODGKINS-LYMPHOMA

      British Journal of Haematology
    41. ANDRE M; HENRYAMAR M; BLAISE D; COLOMBAT P; FLEURY J; MILPIED N; CAHN JY; PICO JL; BASTION Y; KUENTZ M; NEDELLEC G; ATTAL M; FERME C; GISSELBRECHT C
      TREATMENT-RELATED DEATHS AND 2ND CANCER RISK AFTER AUTOLOGOUS STEM-CELL TRANSPLANTATION FOR HODGKINS-DISEASE

      Blood
    42. GISSELBRECHT C; GAULARD P; LEPAGE E; COIFFIER B; BRIERE J; HAIOUN C; CAZALSHATEM D; BOSLY A; XERRI L; TILLY H; BERGER F; BOUHABDALLAH R; DIEBOLD J
      PROGNOSTIC-SIGNIFICANCE OF T-CELL PHENOTYPE IN AGGRESSIVE NON-HODGKINS-LYMPHOMAS

      Blood
    43. ANDRE M; BRICE P; CAZALS D; HENNEQUIN C; FERME C; KERNEIS Y; ROUSSELOT P; ZINI JM; LEPAGE E; GISSELBRECHT C
      RESULTS OF 3 COURSES OF ADRIAMYCIN, BLEOMYCIN, VINDESINE, AND DACARBAZINE WITH SUBTOTAL NODAL IRRADIATION IN 189 PATIENTS WITH NODAL HODGKINS-DISEASE (STAGE-I, STAGE-II AND STAGE-IIIA)

      HEMATOLOGY AND CELL THERAPY
    44. MARIN GH; DALCORTIVO L; CAYUELA JM; MAROLLEAU JP; PAUTIER P; COJEANZELEK I; BRICE P; MAKKE J; BENBUNAN M; GISSELBRECHT C
      PERIPHERAL-BLOOD STEM-CELL CD34+ AUTOLOGOUS TRANSPLANT IN RELAPSED FOLLICULAR LYMPHOMA

      HEMATOLOGY AND CELL THERAPY
    45. TIRELLI U; ERRANTE D; SANTAROSSA S; SPINA M; GISSELBRECHT C; MAROLLEAU JP; KERNEIS Y; RIDOLFO A; BOTTURA P; PAN A; DELLEFOGLIE P; ROSSI G; TAVIO M; VACCHER E
      EPIRUBICIN, BLEOMYCIN, VINBLASTINE AND PREDNISONE (EBVP) CHEMOTHERAPY(CT) IN COMBINATION WITH ANTIRETROVIRAL THERAPY AND PRIMARY USE OF G-CSF FOR PATIENTS (PTS) WITH HODGKINS-DISEASE AND HIV-INFECTION (HD-HIV)

      Journal of acquired immune deficiency syndromes and human retrovirology
    46. GISSELBRECHT C; SPINA M; GABARRE J; RIZZARDINI G; SCHLAIFER D; NIGRA E; BOUABDALLAH R; SCHRAPPE M; RAPOPORT B; CARBONE C; RAPHAEL M; TIRELLI U
      THERAPY OF HIV-RELATED NON-HODGKINS-LYMPHOMA - AN EUROPEAN MULTICENTRIC RANDOMIZED STUDY IN PATIENTS STRATIFIED ACCORDING TO THEIR PROGNOSTIC FACTORS - PRELIMINARY-RESULTS

      Journal of acquired immune deficiency syndromes and human retrovirology
    47. GISSELBRECHT C; HAIOUN C; LEPAGE E; BASTION Y; TILLY H; BOSLY A; DUPRIEZ B; MARIT G; HERBRECHT R; DECONINCK E; MAROLLEAU JP; YVER A; DABOUZHARROUCHE F; COIFFIER B; REYES F
      PLACEBO-CONTROLLED PHASE-III STUDY OF LENOGRASTIM (GLYCOSYLATED RECOMBINANT HUMAN GRANULOCYTE-COLONY-STIMULATING FACTOR) IN AGGRESSIVE NON-HODGKINS-LYMPHOMA - FACTORS INFLUENCING CHEMOTHERAPY ADMINISTRATION

      Leukemia & lymphoma
    48. WENDUM D; SEBBAN C; GAULARD P; COIFFIER B; TILLY H; CAZALS D; BOEHN A; CASASNOVAS RO; BOUABDALLAH R; JAUBERT J; FERRANT A; DIEBOLD J; DEMASCAREL A; GISSELBRECHT C
      FOLLICULAR LARGE-CELL LYMPHOMA TREATED WITH INTENSIVE CHEMOTHERAPY - AN ANALYSIS OF 89 CASES INCLUDED IN THE LNH87 TRIAL AND COMPARISON WITH THE OUTCOME OF DIFFUSE LARGE B-CELL LYMPHOMA

      Journal of clinical oncology
    49. HAIOUN C; LEPAGE E; GISSELBRECHT C; BASTION Y; COIFFIER B; BRICE P; BOSLY A; DUPRIEZ B; NOUVEL C; TILLY H; LEDERLIN P; BIRON P; BRIERE J; GAULARD P; REYES F
      BENEFIT OF AUTOLOGOUS BONE-MARROW TRANSPLANTATION OVER SEQUENTIAL CHEMOTHERAPY IN POOR-RISK AGGRESSIVE NON-HODGKINS-LYMPHOMA - UPDATED RESULTS OF THE PROSPECTIVE-STUDY LNH87-2

      Journal of clinical oncology
    50. CHEZE S; GAULARD P; COIFFIER B; BOULAT O; BAGLIN AC; BAUMELOU E; RAYMONDGELLE MC; GISSELBRECHT C; DIEBOLD J; LEPORRIER M
      NASAL T-NATURAL-KILLER (NK) CELL LYMPHOMA - CLINICOPATHOLOGICAL STUDYOF 10 CASES FROM THE GELA LNH-87 PROTOCOL

      Blood
    51. HAIOUN C; LEPAGE E; SALLES G; MOREL P; GABARRE J; LEDERLIN P; TILLY H; BOSLY A; GAULARD P; COIFFIER B; GISSELBRECHT C; REYES F
      BONE-MARROW INVOLVEMENT AND LOW SERUM-ALBUMIN LEVEL ARE USEFUL TO BETTER PREDICT SURVIVAL OF POOR-RISK PATIENTS WITH AGGRESSIVE LYMPHOMA ASDEFINED BY THE AGE-ADJUSTED INTERNATIONAL PROGNOSTIC INDEX (AA-IPI)

      Blood
    52. SIMON D; GISSELBRECHT C; SEBBAN C; REYES F; BOSLY A; GABARRE J; MOREL P; BOULAT O; LEPAGE E
      IDENTIFICATION OF INFECTION PROGNOSTIC FACTORS IN AGGRESSIVE NON-HODGKIN LYMPHOMAS TREATED WITH MYELOSUPPRESSIVE CYCLES OF CHEMOTHERAPY

      Blood
    53. REMAN O; BROUSSE N; SOLALCELIGNY P; MORELLO R; LEDERLIN P; CHRISTIAN D; MOREL P; BLANC M; PICO J; BOULAT O; CONROY T; GISSELBRECHT C; HAIOUN C; MARTIN D; TURLURE P; SIMON M; DABOUT D; LEPORRIER M
      2-CHLORODEOXYADENOSINE (2CDA) IN RELAPSING OR REFRACTORY FOLLICULAR LYMPHOMA

      Blood
    54. HAIOUN C; GISSELBRECHT C; QUESNEL B; MOREL P; REYES F
      DOUBLE AUTOTRANSPLANT (DAT) AS FIRST LINE CONSOLIDATIVE TREATMENT IN POOR-RISK AGGRESSIVE LYMPHOMA - A PILOT-STUDY OF 31 PATIENTS

      Blood
    55. MOREL P; MUNCK JN; COIFFIER B; GISSELBRECHT C; LEDERLIN P; LAVAUD A; BOSLY A; TILLY H; QUESNEL B; THYSS A; SCHLAIFER D; BRIERE J; REYES F
      ECVB - A NEW HIGH-DOSE CHOP REGIMEN FOLLOWED BY AN INTENSIVE CONSOLIDATION IN PATIENTS (PTS) AGED LESS-THAN-OR-EQUAL-TO-60 YEARS WITH AGGRESSIVE LYMPHOMA (NHL) PRESENTING WITH ONLY ONE ADVERSE PROGNOSTIC FACTOR OF THE INTERNATIONAL PROGNOSTIC INDEX (IPI) - AN INTERIM ANALYSIS OFTHE LNH93-2 PROTOCOL ON 433 PTS

      Blood
    56. BOSLY A; SONET A; SALLES G; BRICE P; HAIOUN C; KERNEIS Y; TILLY H; LEDERLIN P; PLANTIER I; SEBBAN C; GISSELBRECHT C; COIFFIER B
      SUPERIORITY OF LATE OVER EARLY INTENSIFICATION IN RELAPSING REFRACTORY AGGRESSIVE NON-HODGKINS-LYMPHOMA - A RANDOMIZED STUDY FROM THE GELA - LNH RP-93/

      Blood
    57. REYES F; LEPAGE E; MOREL P; LEDERLIN P; COIFFIER B; TILLY H; BOSLY A; GABARRE J; BRIERE J; FILLET G; MOLINA T; GISSELBRECHT C
      FAILURE OF FIRST-LINE INDUCTIVE HIGH-DOSE CHEMOTHERAPY (HDC) IN POOR-RISK PATIENTS (PTS) WITH AGGRESSIVE LYMPHOMA - UPDATED RESULTS OF THE RANDOMIZED LNH93-3 STUDY

      Blood
    58. GISSELBRECHT C
      AUTOLOGOUS STEM-CELL TRANSPLANTATION IN AGGRESSIVE NON-HODGKINS-LYMPHOMA

      HEMATOLOGY AND CELL THERAPY
    59. BRICE P; MAROLLEAU JP; PAUTIER P; MAKKE J; CAZALS D; DOMBRET H; DAGAY MF; BENBUNAN M; GISSELBRECHT C
      HEMATOLOGIC RECOVERY AND SURVIVAL OF LYMPHOMA PATIENTS AFTER AUTOLOGOUS STEM-CELL TRANSPLANTATION - COMPARISON OF BONE-MARROW AND PERIPHERAL-BLOOD PROGENITOR CELLS

      Leukemia & lymphoma
    60. GUERCI A; LEDERLIN P; REYES F; BORDESSOULE D; SEBBAN C; TILLY H; KERNEIS Y; BIRON P; GISSELBRECHT C; HERBRECHT R; COIFFIER B
      EFFECT OF GRANULOCYTE-COLONY-STIMULATING FACTOR ADMINISTRATION IN ELDERLY PATIENTS WITH AGGRESSIVE NON-HODGKINS-LYMPHOMA TREATED WITH A PIRARUBICIN-COMBINATION CHEMOTHERAPY REGIMEN

      Annals of oncology
    61. SWEETENHAM JW; PEARCE R; TAGHIPOUR G; BLAISE D; GISSELBRECHT C; GOLDSTONE AH
      ADULT BURKITT AND BURKITT-LIKE NON-HODGKINS-LYMPHOMA - OUTCOME FOR PATIENTS TREATED WITH HIGH-DOSE THERAPY AND AUTOLOGOUS STEM-CELL TRANSPLANTATION IN FIRST REMISSION OR AT RELAPSE - RESULTS FROM THE UROPEAN-GROUP-FOR-BLOOD-AND-MARROW-TRANSPLANTATION

      Journal of clinical oncology
    62. BLAISE D; ATTAL M; REIFFERS J; MOLINA L; BELLANGER C; PICO JL; NEDELEC G; VERNANT JP; TROUSSARD X; LEGROS M; GISSELBRECHT C; ROSSI JF; BRANDELY M; HERCEND T; MARANINCHI D
      A PROSPECTIVE RANDOMIZED STUDY OF R-IL2 AFTER AUTOLOGUOUS BMT FOR ACUTE-LEUKEMIA IN CR-1

      Experimental hematology
    63. GISSELBRECHT C; EXTRA JM; LOTZ JP; DEVAUX Y; JANVIER M; PENY AM; GUILLEVIN L; BREMOND D; DELAIN M; HERBRECHT R; LEPAGE E; MARANINCHI D
      CYCLOPHOSPHAMIDE MITOXANTRONE/MELPHALAN (CMA) REGIMEN PRIOR TO AUTOLOGOUS BONE-MARROW TRANSPLANTATION (ABMT) IN METASTATIC BREAST-CANCER/

      Bone marrow transplantation
    64. MAROLLEAU JP; BRICE P; DALCORTIVO L; FERMAND JP; ROBERT I; MICLEA JM; CHAIBI P; GISSELBRECHT C; MILLS B; KUNKEL L; OLDHAM F; BENBUNAN M
      CD34-300) FOR PATIENTS WITH MALIGNANCIES( SELECTION BY IMMUNOMAGNETICSELECTION (ISOLEX(R))

      Blood
    65. GISSELBRECHT C; LEPAGE E; MOREL P; LEDERLIN P; COIFFIER B; TILLY H; BOSLY A; GABARRE J; BRIERE J; FILLET G; MOLINA T; REVES F
      INTENSIFIED INDUCTION-PHASE INCLUDING AUTOLOGOUS PERIPHERAL STEM-CELLTRANSPLANTATION DOES NOT IMPROVE RESPONSE RATE AND SURVIVAL IN LYMPHOMA WITH AT LEAST 2 ADVERSE PROGNOSTIC FACTORS WHEN COMPARED TO ACVB REGIMEN

      Blood
    66. ANDRE M; HENRYAMAR M; PICO JL; BASTION Y; BLAISE D; KUENTZ M; COLOMBAT P; CAHN JY; ATTAL M; FLEURY J; MILPIED N; BIRON P; NEDELLEC G; JOUET JP; TILLY R; FERME C; GISSELBRECHT C
      AUTOLOGOUS STEM-CELL TRANSPLANTATION (ASCT) IMPROVES SURVIVAL OF REFRACTORY HODGKINS-DISEASE (HD) PATIENTS - A RETROSPECTIVE MATCH-CONTROLLED STUDY

      Blood
    67. GISSELBRECHT C; GAULARD P; LEPAGE E; COIFFIER B; BRIERE FJ; HAIOUN C; CAZALS D; BOSLY A; XERRI L; TILLY H; BERGER F; BOUHABDALLAH R; DIEBOLD J
      PROGNOSTIC-SIGNIFICANCE OF T-CELL PHENOTYPE IN AGGRESSIVE NON-HODGKINS-LYMPHOMAS

      Blood
    68. DETOURMIGNIES L; COPIN MC; MOREL P; VANRUMBEKE M; PREUDHOMME C; WATTEL E; GAULARD P; GISSELBRECHT C; GOSSELIN B; FENAUX P
      P53 OVEREXPRESSION IN DIFFUSE LARGE-CELL LYMPHOMA (DLCL) AND ITS PROGNOSTIC VALUE BY MULTIPARAMETER ANALYSIS

      Blood
    69. SOLALCELIGNY P; LEPAGE E; BROUSSE N; TERTIAN G; THYSS A; REMAN O; SEBBAN C; PIGNON B; GISSELBRECHT C; COIFFIER B; COLE B; SUGANO D; TENDLER C
      A DOXORUBICIN CONTAINING REGIMEN WITH OR WITHOUT INTERFERON-ALPHA-2B (IFN-ALPHA 2B) IN ADVANCED FOLLICULAR LYMPHOMAS - FINAL ANALYSIS OF SURVIVAL, TOXICITY AND QUALITY-OF-LIFE OF THE GELF86 TRIAL

      Blood
    70. BRICE P; GODIN S; LIBERT O; MAROLLEAU JP; MAKKI J; EXTRA JM; FAURE P; GISSELBRECHT C
      EFFECT OF LENOGRASTIN ON THE COST OF AUTOLOGOUS BONE-MARROW TRANSPLANTATION - A PRELIMINARY COMMUNICATION

      PharmacoEconomics
    71. GISSELBRECHT C; FERME C
      PROGNOSTIC FACTORS IN ADVANCED HODGKINS-DISEASE - PROBLEMS AND PITFALLS - TOWARDS AN INTERNATIONAL PROGNOSTIC INDEX

      Leukemia & lymphoma
    72. GISSELBRECHT C
      PERIPHERAL-BLOOD PROGENITOR CELLS (PBPC) AND TREATMENT OF NON-HODGKINS-LYMPHOMA

      European journal of cancer
    73. GABARRE J; LEPAGE E; THYSS A; TUBIANA R; BASTION Y; SCHLAIFER D; SEBBAN C; RIBRAG V; FERERES M; RAPHAEL M; GISSELBRECHT C
      CHEMOTHERAPY COMBINED WITH ZIDOVUDINE AND GM-CSF IN HUMAN IMMUNODEFICIENCY VIRUS-RELATED NON-HODGKINS-LYMPHOMA

      Annals of oncology
    74. MOUNIER N; PAUTIER P; DEKERVILER E; KERNEIS Y; GISSELBRECHT C; BRICE P
      LYMPHOPLASMOCYTIC MALIGNANT-LYMPHOMA PRESENTING WITH SPINAL EPIDURAL INVOLVEMENT - 4 REPORTS OF THIS UNCOMMON LESION

      American journal of hematology
    75. GISSELBRECHT C
      TREATMENT OF ADULT INTERMEDIATE GRADE NON -HODGKINS-LYMPHOMA

      La Revue de medecine interne
    76. LOTZ JP; PENE F; BOULEUC C; ANDRE T; GISSELBRECHT C; BONNAK H; MERAD Z; ESTESO A; MICCIOBELLAICHE A; AVENIN D; DONSIMONI R; FIRMIN C; GLIGOROV J; MORVAN F; PHILIPPE G; CHEVALLIER D; HING JM; SEKNAZI C; PROT C; BENMILOUD M; OUDARD S; CHOPIERRICHAUD J; GEROTA J; IZRAEL V
      HIGH-DOSE CHEMOTHERAPY AND AUTOLOGOUS STE M-CELL SUPPORT FOR THE TREATMENT OF SOLID TUMORS IN ADULTS .2. PRINCIPLES, ORGANIZATION AND APPLICATION TO THE TREATMENT OF GERM-CELL, TROPHOBLASTIC, MAMMARY, OVARIAN AND SMALL-CELL BRONCHOGENIC CANCERS

      La Revue de medecine interne
    77. LOTZ JP; PENE F; BOULEUC C; ANDRE T; GISSELBRECHT C; BONNAK H; MERAD Z; ESTESO A; MICCIOBELLAICHE A; AVENIN D; DONSIMONI R; FIRMIN C; GLIGOROV J; CHEVALLIER D; SEKNAZI C; PROT C; BENMILOUD M; OUDARD S; CHOPIERRICHAUD J; IZRAEL V
      HIGH-DOSE CHEMOTHERAPY AND AUTOLOGOUS STE M-CELL SUPPORT FOR THE TREATMENT OF SOLID TUMORS IN ADULTS .1.

      La Revue de medecine interne
    78. PHILIP T; GUGLIELMI C; HAGENBEEK A; SOMERS R; VANDERLELIE H; BRON D; SONNEVELD P; GISSELBRECHT C; CAHN JY; HAROUSSEAU JL; COIFFIER B; BIRON P; MANDELLI F; CHAUVIN F
      AUTOLOGOUS BONE-MARROW TRANSPLANTATION AS COMPARED WITH SALVAGE CHEMOTHERAPY IN RELAPSES OF CHEMOTHERAPY-SENSITIVE NON-HODGKINS-LYMPHOMA

      The New England journal of medicine
    79. GISSELBRECHT C
      INTENSIVE CHEMOTHERAPY WITH BONE-MARROW G RAFT - ASSESSMENT AND LIMITS - THE FUTURE

      Bulletin du cancer
    80. BASTION Y; BRICE P; HAIOUN C; SONET A; SALLES G; MAROLLEAU JP; ESPINOUSE D; REYES F; GISSELBRECHT C; COIFFIER B
      INTENSIVE THERAPY WITH PERIPHERAL-BLOOD PROGENITOR-CELL TRANSPLANTATION IN 60 PATIENTS WITH POOR-PROGNOSIS FOLLICULAR LYMPHOMA

      Blood
    81. HAIOUN C; LEPAGE E; GISSELBRECHT C; BASTION Y; DOYEN C; PLANTIER I; SCHLAIFER D; TILLY H; DECONINCK E; BORDESSOULE D; GAULARD P; REYES F
      AUTOLOGOUS TRANSPLANTATION VERSUS CONVENTIONAL SALVAGE THERAPY IN AGGRESSIVE NON-HODGKINS-LYMPHOMA (NHL) PARTIALLY RESPONDING TO FIRST LINECHEMOTHERAPY - A STUDY OF 96 PATIENTS ENROLLED IN THE LNH87-2 PROTOCOL

      Blood
    82. SEBBAN C; WENDUM D; GAULARD P; COIFFIER B; CAZALS D; GABARRE J; CASANOVAS O; BOUABDALLAH R; JAUBERT J; FILLET G; DIEBOLD J; GISSELBRECHT C
      FOLLICULAR LARGE-CELL LYMPHOMA (FLCL) TREATED BY INTENSIVE CHEMOTHERAPY - AN ANALYSIS OF 89 CASES INCLUDED IN THE LNH87 TRIAL END COMPARISON WITH THE OUTCOME OF DIFFUSE LARGE-CELL LYMPHOMA (DLCL)

      Blood
    83. HAIOUN C; LEPAGE E; GISSELBRECHT C; COIFFIER B; BOSLY A; DUPRIEZ B; NOUVEL C; TILLY H; LEDERLIN P; BIRON P; BRIERE J; GAULARD P; REVES F
      AUTOLOGOUS BONE-MARROW TRANSPLANTATION (ABMT) VERSUS SEQUENTIAL CHEMOTHERAPY FOR AGGRESSIVE NON-HODGKINS-LYMPHOMA (NHL) IN FIRST COMPLETE REMISSION (CR) - A STUDY OF 542 PATIENTS (LNH87-2 PROTOCOL)

      Blood
    84. HAGENBEEK A; GUGLIELMI C; CHAUVIN F; VANDERLELY J; BRON D; SONNEVELD P; GISSELBRECHT C; CAHN JY; HAROUSSEAU JL; COIFFIER B; BIRON P; SOMERS R; PHILIP T
      AUTOLOGOUS BONE-MARROW TRANSPLANTATION VERSUS CONVENTIONAL CHEMOTHERAPY IN PATIENTS WITH RELAPSED DIFFUSE NONHODGKINS LYMPHOMA - RESULTS FROM A PROSPECTIVE, RANDOMIZED PHASE-III CLINICAL-TRIAL IN 216 PATIENTS (THE PARMA STUDY)

      Blood
    85. ANDRE M; HENRYAMAR M; BLAISE D; COLOMBAT P; FLEURY J; MILPIED N; GAHN JY; PICO JL; BASTION Y; KUENTZ M; BIRON P; FERME C; GISSELBRECHT C
      INCIDENCE OF 2ND CANCERS (SC) AND CAUSES OF DEATH AFTER AUTOLOGOUS STEM-CELL TRANSPLANTATION (ASCT) FOR HODGKINS-DISEASE (HD)

      Blood
    86. MAROLLEAU JP; BACCARD M; FLAGEUL B; RYBOJAD M; LAROCHE L; VEROLA O; BRANDELY M; MOREL P; GISSELBRECHT C
      HIGH-DOSE RECOMBINANT INTERLEUKIN-2 IN ADVANCED CUTANEOUS T-CELL LYMPHOMA

      Archives of dermatology
    87. GEISSMANN F; DEROUIN F; MAROLLEAU JP; GISSELBRECHT C; BRICE P
      DISSEMINATED TOXOPLASMOSIS FOLLOWING AUTOLOGOUS BONE-MARROW TRANSPLANTATION

      Clinical infectious diseases
    88. RACADOT E; SEBBAN C; BOUCHEIX C; DAVID B; ATTAL M; REIFFERS J; GISSELBRECHT C; VERNANT J; TROUSSARD X; HERVE P; FIERE D
      AUTOLOGOUS BMT FOR POSTREMISSION THERAPY IN ADULT ALL - AN IMMUNOLOGICAL APPROACH

      Leukemia & lymphoma
    89. GISSELBRECHT C
      CHEMOTHERAPY DOSE INTENSITY FACILITATED BY USE OF LENOGRASTIM - IMPLICATIONS FOR QUALITY-OF-LIFE AND SURVIVAL

      European journal of cancer
    90. TREDANIEL J; PEILLON I; FERME C; BRICE P; GISSELBRECHT C; HIRSCH A
      ENDOBRONCHIAL PRESENTATION OF HODGKINS-DISEASE - A REPORT OF 9 CASES AND REVIEW OF THE LITERATURE

      The European respiratory journal
    91. BRICE P; GODIN S; LIBERT O; MAROLLEAU JP; MAKKI J; EXTRA JM; FAURE P; GISSELBRECHT C
      EFFECT OF GRANULOCYTE GROWTH-FACTOR ON TH E COST OF BONE-MARROW AUTOGRAFTS IN ONCOHAEMATOLOGY

      La Presse medicale
    92. HAIOUN C; LEPAGE E; GISSELBRECHT C; COIFFIER B; BOSLY A; TILLY H; MOREL P; NOUVEL C; HERBRECHT R; DAGAY MF; GAULARD P; REYES F
      COMPARISON OF AUTOLOGOUS BONE-MARROW TRANSPLANTATION WITH SEQUENTIAL CHEMOTHERAPY FOR INTERMEDIATE-GRADE AND HIGH-GRADE NON-HODGKINS-LYMPHOMA IN FIRST COMPLETE REMISSION - A STUDY OF 464 PATIENTS

      Journal of clinical oncology
    93. GISSELBRECHT C; BRICE P
      UTILIZATION OF PERIPHERAL-BLOOD STEM-CELL S IN INTENSIVE CHEMOTHERAPYOF LYMPHOMAS

      Pathologie et biologie
    94. EXTRA JM; ESPIE M; BOURSTYN E; DEROQUANCOURT A; MAYLIN C; GISSELBRECHT C; MARTY M
      HIGH-DOSE INDUCTION CHEMOTHERAPY (SIM-85) IN INFLAMMATORY BREAST-CANCER

      Pathologie et biologie
    95. BRICE P; DIVINE M; MAROLLEAU JP; HAIOUN C; DALCORTIVO L; SITTHY X; BEAUJEAN F; NOROL F; BENBUNAN M; REYES F; GISSELBRECHT C
      COMPARISON OF AUTOGRAFTING USING MOBILIZED PERIPHERAL-BLOOD STEM-CELLS WITH AND WITHOUT GRANULOCYTE-COLONY-STIMULATING FACTOR IN MALIGNANT-LYMPHOMAS

      Bone marrow transplantation
    96. BASTION Y; REYES F; BOSLY A; GISSELBRECHT C; YVER A; GILLES E; MARAL J; COIFFIER B
      POSSIBLE TOXICITY WITH THE ASSOCIATION OF G-CSF AND BLEOMYCIN

      Lancet
    97. GISSELBRECHT C
      PLACEBO-CONTROLLED PHASE-III TRIAL OF LENOGRASTIM IN BONE-MARROW TRANSPLANTATION (VOL 343, PG 696, 1994)

      Lancet
    98. GISSELBRECHT C; PRENTICE HG; BACIGALUPO A; BIRON P; MILPIED N; RUBIE H; CUNNINGHAM D; LEGROS M; PICO JL; LINCH DC; BURNETT AK; SCARFFE JH; SIEGERT W; YVER A
      PLACEBO-CONTROLLED PHASE-III TRIAL OF LENOGRASTIM IN BONE-MARROW TRANSPLANTATION

      Lancet
    99. BRICE P; PAUTIER P; MAROLLEAU JP; CASTAIGNE S; GISSELBRECHT C
      PREGNANCY AFTER AUTOLOGOUS BONE-MARROW TRANSPLANTATION FOR MALIGNANT-LYMPHOMAS

      Nouvelle revue francaise d'hematologie
    100. MOREL P; DUPRIEZ B; HERBRECHT R; BASTION Y; TILLY H; DELANNOY A; HAIOUN C; NOUVEL C; BOUABDALLAH K; BAUMELOU E; GISSELBRECHT C
      AGGRESSIVE LYMPHOMAS WITH RENAL INVOLVEMENT - A STUDY OF 48 PATIENTS TREATED WITH THE LNH-84 AND LNH-87 REGIMENS

      British Journal of Cancer


ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 25/01/21 alle ore 09:22:58